收费全文 | 1344928篇 |
免费 | 115434篇 |
国内免费 | 6384篇 |
耳鼻咽喉 | 16762篇 |
儿科学 | 43337篇 |
妇产科学 | 36815篇 |
基础医学 | 184739篇 |
口腔科学 | 36342篇 |
临床医学 | 121953篇 |
内科学 | 279978篇 |
皮肤病学 | 31987篇 |
神经病学 | 111503篇 |
特种医学 | 55701篇 |
外国民族医学 | 274篇 |
外科学 | 211074篇 |
综合类 | 31606篇 |
现状与发展 | 2篇 |
一般理论 | 429篇 |
预防医学 | 108156篇 |
眼科学 | 28170篇 |
药学 | 94379篇 |
5篇 | |
中国医学 | 2230篇 |
肿瘤学 | 71304篇 |
2018年 | 13728篇 |
2017年 | 10930篇 |
2016年 | 13123篇 |
2015年 | 14588篇 |
2014年 | 20322篇 |
2013年 | 30273篇 |
2012年 | 36996篇 |
2011年 | 39649篇 |
2010年 | 24762篇 |
2009年 | 24210篇 |
2008年 | 36892篇 |
2007年 | 39337篇 |
2006年 | 40403篇 |
2005年 | 38922篇 |
2004年 | 37132篇 |
2003年 | 36180篇 |
2002年 | 34169篇 |
2001年 | 66122篇 |
2000年 | 67963篇 |
1999年 | 56643篇 |
1998年 | 16780篇 |
1997年 | 15060篇 |
1996年 | 16057篇 |
1995年 | 16265篇 |
1994年 | 15128篇 |
1993年 | 14182篇 |
1992年 | 47130篇 |
1991年 | 45776篇 |
1990年 | 44004篇 |
1989年 | 41837篇 |
1988年 | 38777篇 |
1987年 | 38096篇 |
1986年 | 35879篇 |
1985年 | 34650篇 |
1984年 | 26376篇 |
1983年 | 22118篇 |
1982年 | 13855篇 |
1981年 | 12451篇 |
1980年 | 11723篇 |
1979年 | 23550篇 |
1978年 | 17079篇 |
1977年 | 14389篇 |
1976年 | 13185篇 |
1975年 | 13728篇 |
1974年 | 16098篇 |
1973年 | 15396篇 |
1972年 | 14175篇 |
1971年 | 13037篇 |
1970年 | 11880篇 |
1969年 | 11104篇 |
Areas covered: the principal pharmacogenetic and non-genetic differences in the pharmacology of tamoxifen and endoxifen are evaluated. To this end, references from PubMed, Embase or Web of Science, among others, were reviewed As non-genetic factors, important differences and similarities such age, or adherence to tamoxifen therapy are comprehensively illustrated. Additionally, since CYP2D6 genotypes are considered the main limitation of tamoxifen, many studies have investigated the association between the worsened clinical outcomes in patients with non-functional CYP2D6 genotypes. In this review, an overview of the research on this field is presented. Also, a summary describing the literature about individualizing tamoxifen therapy with endoxifen concentrations and its limitations is listed.
Expert opinion: z-endoxifen hydrochloride is only investigated in the metastatic setting, still more research is required before its place in therapeutics is known. Similarly, monitoring tamoxifen efficacy based on endoxifen concentrations might not be overall recommended due to the limited evidence available. 相似文献
Background
Etomidate is frequently selected over propofol for induction of anaesthesia because of a putatively favourable haemodynamic profile, but data confirming this perception are limited.Methods
Patients undergoing cardiac surgery were randomised to induction of anaesthesia with propofol or etomidate. Phase I (n=75) was conducted as open-label, whereas Phase II (n=75) was double blind. Mean arterial blood pressure (MAP) and boluses of vasopressor administered after induction were recorded. The primary endpoint was the area under the curve below baseline MAP (MAP-time integral) during the 10 min after induction. Secondary endpoints were the use of vasopressors over the same period, and the effect of blinding on the aforementioned endpoints. Groups were compared using regression models with phase and anaesthetist as factors.Results
The mean difference between etomidate and propofol in the MAP-time integral below baseline was 2244 mm Hg s (95% confidence interval, 581–3906; P=0.009), representing a 34% greater reduction with propofol. Overall, vasopressors were used in 10/75 patients in the etomidate group vs 21/75 in the propofol group (P=0.38), and in 20/74 patients during the blinded phase vs 11/76 during the open-label phase (P=0.31). The interaction between randomisation and phase (open-labelled or blinded) was not significant for either primary (P=0.73) or secondary endpoints (P=0.90).Conclusions
Propofol caused a 34% greater reduction in MAP-time integral from baseline after induction of anaesthesia than etomidate, despite more frequent use of vasopressors with propofol, confirming the superior haemodynamic profile of etomidate in this context. The proportion of patients receiving vasopressors increased slightly, albeit not significantly, in both groups in the blinded phase.Clinical trial registration
Australian and New Zealand Clinical Trials Registry, ACTRN12614000717651. 相似文献![点击此处可从《Journal of cardiovascular electrophysiology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
![点击此处可从《Addiction (Abingdon, England)》网站下载免费的PDF全文](/ch/ext_images/free.gif)